Literature DB >> 28102692

De Novo Assembly of Highly Substituted Morpholines and Piperazines.

Pravin Patil1, Rudrakshula Madhavachary1, Katarzyna Kurpiewska2, Justyna Kalinowska-Tłuścik2, Alexander Dömling1.   

Abstract

The morpholine and piperazine with their remarkable physical and biochemical properties are popular heterocycles in organic and medicinal chemistry used in rational property design. However, in the majority of cases these rings are added to an existing molecule in a building block approach thus limiting their substitution pattern and diversity. Here we introduce a versatile de novo synthesis of the morpholine and piperazine rings using multicomponent reaction chemistry. The large scale amenable building blocks can be further substituted at up to four positions, making this a very versatile scaffold synthesis strategy. Our methods thus fulfill the increasing demand for novel building block design and nontraditional scaffolds which previously were not accessible.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28102692      PMCID: PMC5348101          DOI: 10.1021/acs.orglett.6b03807

Source DB:  PubMed          Journal:  Org Lett        ISSN: 1523-7052            Impact factor:   6.005


Morpholine and piperazines are privileged backbones and are abundantly used as substituents or scaffolds in drugs and medicinal chemistry.[1] They can improve pharmacokinetic (PK) properties of molecules, such as water solubility and metabolic stability, while not being essential for direct receptor binding. They can be introduced by two different general strategies. Often they are attached via a building block approach to the receptor binding motif (Figure , Imatinib). Less often they are built de novo and used as a central scaffold thus merging major receptor binding features with beneficial PK properties. An elegant de novo assembly of these structures is Bode’s SnAP strategy.[2] AMG-8735 is another example of the latter approach; however, it is de novo assembled via an overall lengthy multistep synthesis (∼20 steps).[3] In accordance with the above discussion, it shows major improved properties over the piperidine analogue such as higher metabolic stability in hepatocytes, as well as good pharmacokinetic properties. Clearly a de novo approach has many advantages of the sequential approach, including maximal control over the substitution pattern and improved ligand efficiency. However, often the de novo approach is performed via sequential synthesis and can be time and resource costly. In general, poor commercial availability of substituted morpholines/piperazines and a paucity of methods for their preparation can be observed. Therefore, we would like to report an unprecedented, fast, diverse, and useful multicomponent reaction (MCR) for de novo assembly of piperazine and morpolines.[4]
Figure 1

Examples of bioactive compounds with piperazine and morpholine moieties and two complementary synthesis strategies.

Examples of bioactive compounds with piperazine and morpholine moieties and two complementary synthesis strategies. In order to allow for the fast and diverse assembly of piperazines and morpholines we envisioned a multicomponent Ugi approach followed by a cyclization by an intramolecular SN2 reaction. Here we focus on the tetrazole Ugi reaction which in this context delivers a secondary amine moiety as part of the morpholine/piperazine design. Due to the superior functional group compatibility of MCR in principle, different designs are possible (Scheme ): one where the oxo component delivers the nucleofuge and one based on the amine component.
Scheme 1

Retrosynthetic Design of de Novo Assembly of Morpholines and Piperazines by an MCR Approach

Initially, we envisioned that using an α-halo oxo-component together with an isocyanide, trimethylsilyl azide, and 2-hydroxy or 2-amino or 2-mercaptoethylamine and its derivatives will yield the corresponding Ugi-tetrazole adduct, which under basic conditions should give the corresponding morpholine, piperazine, or thiomorpholine respectively (Scheme A).
Scheme 2

MCR Morpholine or Piperazine Synthesis from A α-Halo Oxo-Component and B α-Hydroxy Oxo-Component

To test this strategy, we decided to use 2-chloroacetaldehyde as an electrophile and p-chlorobenzyl isocyanide, trimethylsilyl azide, and ethanolamine as a nucleophile, each 1 equiv, in methanol stirred for 18 h at room temperature (see Scheme A). We observed the Ugi-adduct formation (4), which was further in situ treated with various bases to give the corresponding morpholine derivative (6); however, we only observed trace product formation. Next, we decided to change the electrophile and nucleophile positions from the oxo-component and from the amine component respectively (see Scheme B). Unfortunately, in these in situ methods we were unable to isolate the pure products (6). However, after isolating the intermediates 4 and 5, we optimized cyclization conditions with respect to solvents, bases, temperature, and time (Table ).
Table 1

Optimization of Cyclization of Ugi-Adduct to Morpholine

baseequivtemp; timesolvent% yield of 6aa
Et3N223 °C, 18 hCH2Cl2
Et3N223 °C, 5 hCH3CN
DIPEA223 °C, 18 hCH3CN
DBU20–23 °C, 18 hCH3CN
K2CO3223 °C, 18 hCH3CN
K2CO3223 °C, 18 hCH3CN27
KOH223 °C, 18 hCH3CN72
NaOMe1.0–23 °C, 18 hCH3CN51
t-BuOK30–23 °C, 1 hCH3CN79
NaH1.50 °C, 1 hCH3CN85
NaH20–23 °C, 5 hCH3CN30

Isolated yields.

Isolated yields. We observed that sodium hydride (85% yields) and tert-BuOK (79%) in acetonitrile were the optimal base choices for the cyclization. With these optimized conditions, we isolated the intermediate of 4 and 5 and treated with sodium hydride (1.5 eqiuv) in acetonitrile for 1 h at 0 °C to obtain the final cyclized product (6). The Ugi adducts 4a (36%) and 5a (63%) thus give the morpholine derivative 6a in 45% and 85% respectively. With these results, we confirmed that the use of an α-hydroxy oxo-component was higher yielding than that of the α-halo oxo-component. Also, we tested various isocyanides in the Ugi reaction followed by the cyclization. In general, we observed good to excellent yields in both reactions (Table ).
Table 2

MCR for the Ugi-Adduct 4 and 5 and Synthesis of Morpholines 6 Derivativesa,b,c

Yields of isolated, analytically pure compounds after chromatography are given.

The reactions were performed on 1.0 mmol scale using amine (1.0 equiv), aldehyde/ketone (1.0 equiv), isocyanide (1.0 equiv), and NaN3 (1.0 equiv) in MeOH (1.0 M); cyclization reaction was performed in CH3CN using NaH (1.5 equiv) at 0 °C to rt for 1 h.

One-pot overall isolated yield.

Yields of isolated, analytically pure compounds after chromatography are given. The reactions were performed on 1.0 mmol scale using amine (1.0 equiv), aldehyde/ketone (1.0 equiv), isocyanide (1.0 equiv), and NaN3 (1.0 equiv) in MeOH (1.0 M); cyclization reaction was performed in CH3CN using NaH (1.5 equiv) at 0 °C to rt for 1 h. One-pot overall isolated yield. To further simplify the synthesis, we decided to reinvestigate a one-pot Ugi-cyclization procedure. We decided to remove the Ugi solvent methanol after formation of 5a, followed by addition of NaH in acetonitrile at 0 °C for 1 h. Surprisingly, we obtained the morpholine derivatives (6a) in an acceptable 50% yield. To further improve the isolation, we filtered the intermediate (5a) through a short silica bed and cyclized using 1.5 equiv of NaH in acetonitrile to give a morpholine derivative (6a), now in 68% yield. With these optimized conditions, we tested various isocyanides and hydoxyketones and found in general moderate to good yields of 3,3-disubstituted morpholines (Table ). Next, we tested the synthesis of piperazine derivatives first using unsubstituted ethylene diamine. Isolation issues (high water solubility of the Ugi product) and several side products led us to use monoboc-protected ethylene diamine (8) instead (Table ). For example, monoboc-protected ethylenediamine reacted with 2-chloroacetaldehyde, benzyl isocyanide, and trimethylsilyl azide in methanol furnishing the Ugi-tetrazole adduct 9a in a good 71% isolated yield within 12 h. The isolated Ugi-adduct 9a was treated with 3 equiv of trifluoroacetic acid (TFA) in dichloromethane at room temperature for 2 h furnishing the TFA salt of the amine. After removal of the solvent, cyclization was accomplished with tBuOK (3 equiv) in acetonitrile at 60 °C for 1 h, yielding piperazine derivative 10a in 66% overall yield. Different substituted isocyanides in general gave derivatives (10) in good yields (Table-, 10b–10e) including super bulky adamantane isocyanide (10e, 38%). Next, we explored the use of o-phenylenediamine for the synthesis of 2-substituted tetrahydroquinoxaline. Analogously, the monoboc-protected o-phenylenediamine reacted to affod the Ugi tetrazole product 9f (72% yield), which after deprotection and base (NaH) induced cyclization yields the quinoxaline 10f (52%). Moreover, other isocyanides such as benzylisocyanide, 4-chlorobenzyl isocyanide, and linear and branched aliphatic isocyanides also reacted with monoboc-protected o-phenylenediamine, chloroacetaldehyde, and trimethylsilyl azide affording 10g–10l in good yields (Table ).
Table 3

MCR for the Ugi-Adduct of 9 for Piperazine and Tetrahydroquinoxalines 10 Synthesisa,b,c

Method A: cyclization reaction was performed in CH3CN using tBuOK (3.0 equiv) at 60 °C.

Method B: cyclization reaction was performed in CH3CN using NaH (1.5 equiv) at 0 °C to rt for 1 h.

Yields of isolated, analytically pure compounds after chromatography are given. The reactions were performed on 1.0 mmol scale using monobocprotected amine (8, 1.0 equiv), α-halo aldehyde/ketone (1.0 equiv), isocyanides (1.0 equiv), and TMSN3 (1.0 equiv) in MeOH (1.0 M); Boc-deprotection was performed in CH2Cl2 with TFA at rt.

Method A: cyclization reaction was performed in CH3CN using tBuOK (3.0 equiv) at 60 °C. Method B: cyclization reaction was performed in CH3CN using NaH (1.5 equiv) at 0 °C to rt for 1 h. Yields of isolated, analytically pure compounds after chromatography are given. The reactions were performed on 1.0 mmol scale using monobocprotected amine (8, 1.0 equiv), α-halo aldehyde/ketone (1.0 equiv), isocyanides (1.0 equiv), and TMSN3 (1.0 equiv) in MeOH (1.0 M); Boc-deprotection was performed in CH2Cl2 with TFA at rt. Furthermore, to underscore the usefulness of the produced scaffolds we showcase some further transformations of the secondary amine of morpholines and piperazines via reductive amination (11, 72%), sulfonation (12, 72%), acylation (15, 54%), and urea (13, 39%) and thiourea (14, 16, 61%, 33%) formation (Scheme ).
Scheme 3

Further Functionalization of Morpholines and Piperazines

Several crystal structures also have been obtained and support the proposed structures of the scaffolds (Figure ).
Figure 2

Crystal structures of 6a, 6f, 6j, and 6t were confirmed by X-ray analysis.

Crystal structures of 6a, 6f, 6j, and 6t were confirmed by X-ray analysis. Morpholines and piperazines are among the 25 most frequent nitrogen heterocycles in U.S. FDA approved drugs.[5] From a medicinal chemistry design standpoint of view, morpholines and piperazines are outstanding since they combine three-dimensionality with superior PK properties. “Escape from flatland”, i.e. saturation, correlates well with solubility, an experimental physical property important to success in the drug discovery setting.[6] Based on the excellent scaffold properties these scaffolds are now part of the screening decks of the European Lead Factory (ELF).[7−12] In summary, we have identified a novel method for the synthesis of substituted N-unprotected piperazines, morpholines, and tetrahydroquinoxalines. This robust and operationally simple two-step, air- and moisture-tolerant procedure is a valuable addition to MCR chemistry and expands its unique scaffold diversity. Work is ongoing to identify valuable biological targets for our compound libraries and will be reported in due course.
  9 in total

1.  Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective.

Authors:  Anna Karawajczyk; Fabrizio Giordanetto; Jorg Benningshof; Daniel Hamza; Tuomo Kalliokoski; Kees Pouwer; Remy Morgentin; Adam Nelson; Gerhard Müller; Alexander Piechot; Dimitrios Tzalis
Journal:  Drug Discov Today       Date:  2015-09-30       Impact factor: 7.851

Review 2.  The ELF Honest Data Broker: informatics enabling public-private collaboration in a precompetitive arena.

Authors:  Guillaume Paillard; Philip Cochrane; Philip S Jones; Willem P van Hoorn; Andrei Caracoti; Herman van Vlijmen; Andrew D Pannifer
Journal:  Drug Discov Today       Date:  2015-11-19       Impact factor: 7.851

3.  Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction.

Authors:  Ana Z Gonzalez; John Eksterowicz; Michael D Bartberger; Hilary P Beck; Jude Canon; Ada Chen; David Chow; Jason Duquette; Brian M Fox; Jiasheng Fu; Xin Huang; Jonathan B Houze; Lixia Jin; Yihong Li; Zhihong Li; Yun Ling; Mei-Chu Lo; Alexander M Long; Lawrence R McGee; Joel McIntosh; Dustin L McMinn; Jonathan D Oliner; Tao Osgood; Yosup Rew; Anne Y Saiki; Paul Shaffer; Sarah Wortman; Peter Yakowec; Xuelei Yan; Qiuping Ye; Dongyin Yu; Xiaoning Zhao; Jing Zhou; Steven H Olson; Julio C Medina; Daqing Sun
Journal:  J Med Chem       Date:  2014-03-04       Impact factor: 7.446

4.  Innovative approaches to the design and synthesis of small molecule libraries.

Authors:  Adam Nelson; Didier Roche
Journal:  Bioorg Med Chem       Date:  2015-02-28       Impact factor: 3.641

5.  European lead factory opens for business.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

Review 6.  Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals.

Authors:  Edon Vitaku; David T Smith; Jon T Njardarson
Journal:  J Med Chem       Date:  2014-10-07       Impact factor: 7.446

7.  The Joint European Compound Library: boosting precompetitive research.

Authors:  Jérémy Besnard; Philip S Jones; Andrew L Hopkins; Andrew D Pannifer
Journal:  Drug Discov Today       Date:  2014-09-06       Impact factor: 7.851

8.  Catalytic Synthesis of N-Unprotected Piperazines, Morpholines, and Thiomorpholines from Aldehydes and SnAP Reagents.

Authors:  Michael U Luescher; Jeffrey W Bode
Journal:  Angew Chem Int Ed Engl       Date:  2015-07-23       Impact factor: 15.336

9.  Escape from flatland: increasing saturation as an approach to improving clinical success.

Authors:  Frank Lovering; Jack Bikker; Christine Humblet
Journal:  J Med Chem       Date:  2009-11-12       Impact factor: 7.446

  9 in total
  7 in total

1.  With unprotected amino acids to tetrazolo peptidomimetics.

Authors:  Rudrakshula Madhavachary; Qian Wang; Alexander Dömling
Journal:  Chem Commun (Camb)       Date:  2017-07-27       Impact factor: 6.222

2.  Diastereoselective One Pot Five-Component Reaction toward 4-(Tetrazole)-1,3-Oxazinanes.

Authors:  Ajay L Chandgude; Daniele Narducci; Katarzyna Kurpiewska; Justyna Kalinowska-Tłuścik; Alexander Dömling
Journal:  RSC Adv       Date:  2017-10-26       Impact factor: 3.361

3.  Synthesis and characterization of novel acyl hydrazones derived from vanillin as potential aldose reductase inhibitors.

Authors:  Yeliz Demir; Feyzi Sinan Tokalı; Erbay Kalay; Cüneyt Türkeş; Pelin Tokalı; Osman Nuri Aslan; Kıvılcım Şendil; Şükrü Beydemir
Journal:  Mol Divers       Date:  2022-09-14       Impact factor: 3.364

Review 4.  Tetrazoles via Multicomponent Reactions.

Authors:  Constantinos G Neochoritis; Ting Zhao; Alexander Dömling
Journal:  Chem Rev       Date:  2019-02-01       Impact factor: 60.622

5.  Highly Stereoselective Synthesis of a Compound Collection Based on the Bicyclic Scaffolds of Natural Products.

Authors:  Murali Annamalai; Stanimira Hristeva; Martyna Bielska; Raquel Ortega; Kamal Kumar
Journal:  Molecules       Date:  2017-05-18       Impact factor: 4.411

6.  Synthesis of Highly Substituted Imidazole Uracil Containing Molecules via Ugi-4CR and Passerini-3CR.

Authors:  Rudrakshula Madhavachary; Tryfon Zarganes-Tzitzikas; Pravin Patil; Katarzyna Kurpiewska; Justyna Kalinowska-Tłuścik; Alexander Dömling
Journal:  ACS Comb Sci       Date:  2018-02-26       Impact factor: 3.784

7.  Combining the Ugi-azide multicomponent reaction and rhodium(III)-catalyzed annulation for the synthesis of tetrazole-isoquinolone/pyridone hybrids.

Authors:  Gerardo M Ojeda; Prabhat Ranjan; Pavel Fedoseev; Lisandra Amable; Upendra K Sharma; Daniel G Rivera; Erik V Van der Eycken
Journal:  Beilstein J Org Chem       Date:  2019-10-16       Impact factor: 2.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.